-
UCB, Inc. et al v. Annora Pharma Private Limited et al DC CAFC
- 1:20-cv-00987
- D. Del.
- Judge: Colm F. Connolly +1
- Filed: 07/24/2020
- Closed: 09/12/2023
- Latest Docket Entry: 11/21/2023
- PACER
- Docket updated daily
2
Plaintiffs
12
Defendants
1
Accused
Product
3
Patents-in-Suit
1,146
Days in
Litigation
-
UCB, Inc. et al v. Annora Pharma Private Limited et al DC CAFC
- 1:20-cv-00987
- D. Del.
- Judge: Colm F. Connolly +1
- Filed: 07/24/2020
- Closed: 09/12/2023
- Latest Docket Entry: 11/21/2023
- PACER
- Docket updated daily
Causes of Action
Infringement
Willful Patent Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
5 |
(2S)-2-[(4R)-2-oxo-4-propylpyrrolidinyl]butanamide or a pharmaceutically acceptable salt thereof.
|
Valid
Entry 250 |
-
Infringement
Annora Pharma Private Limited
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic versions of UCB’s pharmaceutical product Briviact® (brivaracetam) | US 6,911,461 B2 |
5
|
Infringement
Entry 250
|
Apotex Corporation
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic versions of UCB’s pharmaceutical product Briviact® (brivaracetam) | US 6,911,461 B2 |
5
|
Infringement
Entry 250
|
Apotex Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic versions of UCB’s pharmaceutical product Briviact® (brivaracetam) | US 6,911,461 B2 |
5
|
Infringement
Entry 250
|
MSN Laboratories PVT Limited
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic versions of UCB’s pharmaceutical product Briviact® (brivaracetam) | US 6,911,461 B2 |
5
|
Infringement
Entry 250
|
MSN Pharmaceuticals, Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic versions of UCB’s pharmaceutical product Briviact® (brivaracetam) | US 6,911,461 B2 |
5
|
Infringement
Entry 250
|